This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

An Open Study of Triiodothyronine Augmentation of Selective Serotonin Reuptake Inhibitors in Treatment-Resistant Major Depressive Disorder

Dan V. Iosifescu, MD; Andrew A. Nierenberg, MD; David Mischoulon, MD; Roy H. Perlis, MD; George I. Papakostas, MD; Julie L. Ryan, BA; Jonathan E. Alpert, MD; and Maurizio Fava, MD

Published: August 15, 2005

Article Abstract

Objective: In an open trial, we investigated the efficacy of triiodothyronine (T3) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment.

Method: Twenty subjects who met DSM-IV criteria for MDD (mean ± SD age = 44.3 ± 10.3 years; 55% [N = 11] women) and had failed to respond to a course of treatment of at least 8 weeks with an SSRI antidepressant were enrolled in a 4-week open-label augmentation treatment with T3 50 mg/day. Atypical and melancholic subtypes of MDD were diagnosed using Structured Clinical Interview for DSM-IV Axis I Disorders criteria. We administered the 17-item Hamilton Rating Scale for Depression (HAM-D-17) 4 times during the study (which was conducted between 2001 and 2003).

Results: During T3 augmentation, the severity of depression decreased from an initial mean ± SD HAM-D-17 score of 20.5 ± 3.6 to a final HAM-D-17 score of 14.0 ± 7.1 (p = 50%), and 6 subjects (30.0%) achieved clinical remission (final HAM-D-17 <= 7). The 5 subjects with atypical depression experienced significantly (p < .01) greater clinical improvement (final HAM-D-17 scores 6.6 ± 1.8 vs. 16.4 ± 4.5), and higher rates of treatment response (100% [5/5] vs. 13.3% [2/15]) and remission (80.0% [4/5] vs. 13.3% [2/15]), compared to subjects with nonatypical MDD. The 8 subjects with melancholic MDD experienced significantly (p < .05) greater depression severity at the end of the study compared to nonmelancholic MDD subjects (final HAM-D-17 scores = 18.3 ± 6.6 vs. 11.1 ± 6.1).

Conclusion: Triiodothyronine augmentation of SSRIs may be a promising treatment strategy in SSRI-resistant MDD, particularly in subjects with the atypical MDD subtype.

Volume: 66

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF